Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Acalabrutinib (100 mg twice per day) assessed for thrombus formation at injured arterioles of the mice
Smiles: O=C(NC1CCN(CC(F)(F)F)CC1)C1=CN=C(C=C1)C1=CC(F)=CC=C1
Formula: C14H17IN4O2
PubMed PMID: 25108436
potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models
Masitinib Size:2mg solid Acalabrutinib (100 mg twice perMasitinib, also known as AB1010, is an orally bioavailable and multi targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild type and mutated forms of the stem cell factor receptor (c Kit; SCFR); platelet derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor
US$ 137.50
US$ 79.92
US$ 600.00
US$ 143.32
US$ 50.09
US$ 207.00
US$ 68.99
US$ 83.99
US$ 23.62